Andrew Charles
Neurology · Los Angeles, CANPI 1518982453
Payments from drug & device makers
Across 82 payments — averaging $1821.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- H. Lundbeck A S$23K
- Amgen$21K
- Lilly USA, LLC$20K
- Lundbeck LLC$18K
- Pfizer$18K
- plus $17K from 6 others
Across 2 payments — averaging $1824.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
- Pfizer$330
What the payments were for
- Consulting fees$86,43058%
- Speaking & faculty fees$50,03333%
- Travel & lodging$11,4658%
- Food & beverage$1,4371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $31,923 |
| H. Lundbeck A S | 15 | $22,721 |
| Amgen | 10 | $21,056 |
| Lilly USA, LLC | 5 | $20,038 |
| Lundbeck LLC | 6 | $18,275 |
| Pfizer | 8 | $18,089 |
| UCB SA | 2 | $5,170 |
| Biodelivery Sciences International, Inc. | 1 | $3,000 |
| Eli Lilly | 2 | $2,753 |
| Pfizer S.A. | 1 | $2,700 |
| Boehringer Ingelheim International GmbH | 3 | $2,642 |
| Biogen | 1 | $1,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$29,809
- AIMOVIG$21,056
- QULIPTA$20,904
- NURTEC ODT$20,668
- EMGALITY$9,425
- REYVOW$9,163
- UBRELVY$3,304
- ELYXYB - CELECOXIB$3,000
- BOTOX$716
How this compares
$149,365 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dihydroergotamine Mesylate | 12 | $18,761 |
| Emgality PenGalcanezumab-Gnlm | 15 | $12,290 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.